Aeterna Zentaris, Inc.
36Patents
27Active
36Granted
47Portfolio score
Filing activity: May 18, 2001 → May 30, 2018 · 15 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8148546B2 | Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors | Human Necessities | 54 | Active |
| US8192719B2 | Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds | Physics | 18 | Active |
| US8679473B2 | Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof | Emerging Cross-Sectional Technologies | 10 | Active |
| US7276507B2 | Pyridopyrazines and the use thereof as kinase inhibitors | Human Necessities | 6 | Expired |
| US7323468B2 | Pyridopyrazines and the use thereof as kinase inhibitors | Chemistry; Metallurgy | 5 | Expired |
| US7365081B2 | Indole derivatives and their use as medicaments | Chemistry; Metallurgy | 3 | Expired |
| US8202883B2 | Substituted pyrido[2,3-b]pyrazine compounds as modulators of tyrosine kinases | Human Necessities | 2 | Active |
| US10288629B1 | Method of assessing growth hormone deficiency in humans by a macimorelin containing composition | Physics | 1 | Active |
| US8193186B2 | Pyridopyrazines and the use thereof as kinase inhibitors | Chemistry; Metallurgy | 1 | Active |
| US7393834B2 | LHRH-antagonists in the treatment of fertility disorders | Chemistry; Metallurgy | 1 | Expired |
| US7887817B2 | Process for preventing protozoal diseases | Emerging Cross-Sectional Technologies | 1 | Expired |
| US8536332B2 | Modulating signal transduction pathways with substituted pyridol [2,3-b] pyrazines | Human Necessities | 1 | Active |
| US8067456B2 | Tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCPs) | Chemistry; Metallurgy | 1 | Active |
| US8791118B2 | Pyridopyrazines as highly selective ras-Raf-Mek-Erk signal transduction pathway inhibitors | Chemistry; Metallurgy | 0 | Active |
| US8394801B2 | Quinoxaline derivatives and their use for treating benign and malignant tumour disorders | Chemistry; Metallurgy | 0 | Active |
| US7605121B2 | Oligopeptide lyophilisate, their preparation and use | Emerging Cross-Sectional Technologies | 0 | Expired |
| US7288517B2 | Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists | Human Necessities | 0 | Expired |
| US8383607B2 | Perifosine and capecitabine as a combined treatment for cancer | Human Necessities | 0 | Active |
| US8546435B2 | Triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors | Chemistry; Metallurgy | 0 | Active |
| US7741277B2 | Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US8389497B2 | Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals | Human Necessities | 0 | Expired |
| US8541462B2 | Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors | Human Necessities | 0 | Active |
| US8658615B2 | Prohibitin as target for cancer therapy | Physics | 0 | Active |
| US8470776B2 | Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US7718599B2 | Pharmaceutical administration form for peptides, process for its preparation, and use | Human Necessities | 0 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.